InVivoMAb anti-mouse CD96

Combining TIGIT blockade with IL-15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma.

CD96 functions as a co-stimulatory receptor to enhance CD8(+) T cell activation and effector responses.

Tumor-derived soluble CD155 inhibits DNAM-1-mediated antitumor activity of natural killer cells. Okumura G et al., 2020 Mar 2, J Exp Med

CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. Roman Aguilera A et al., 2018, Oncoimmunology

Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.

Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. Blake SJ et al., 2016 Apr, Cancer Discov

Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR.

The murine pan T cell marker CD96 is an adhesion receptor for CD155 and nectin-1.